Johnson & Johnson: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Johnson & Johnson in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Johnson & Johnson's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for Johnson & Johnson over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Johnson & Johnson's performance against key rivals in the prescription pharmaceutical sector* Analyze how J&J will implement lifecycle management strategies across its portfolio as a means to combat patent expiries and generic competition* Assess J&J's diverse healthcare offering and how this will act to maintain operating profit growth despite a forecast decline in Rx drug revenue

[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Johnson & Johnson: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
Despite challenges, J&J’s outlook appears robust
Wide range of strategic options to seek growth
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest quarterly sales
Latest comment
Q4 2010
J&J: looking to expand in the vaccines space
Q3 2010
Q2 2010
Q1 2010
Latest prescription pharma product news
Q4 2010
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Latest corporate news
Q4 2010
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
M&A strategy
Current corporate structure
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Generics analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS
Key findings
Overview
Xarelto
Invega franchise
Simponi
Velcade
Remicade
Procrit
Risperdal franchise
Prezista
APPENDIX
R&D pipeline
Remicade sales reconciliation
References
Abbreviations
Exchange rates

[Inhaltsverzeichnis ausblenden]